



**AGILE THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3 NEW CHOICE STUDY OF AG200-15, AGILE'S NOVEL, LOW-DOSE WEEKLY CONTRACEPTIVE PATCH**

**Rapid Completion of Enrollment Speaks to Patient Desire for More Convenient Contraceptive Options**

**October 4, 2010**

Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive. The NEW CHOICE Study completed enrollment two months ahead of schedule, enabling Agile to plan for an earlier submission of the New Drug Application (NDA) for AG200-15 to the U.S. Food and Drug Administration (FDA).

Dr. Thomas Rossi, Agile's President and CEO, commented, "We are very pleased to complete enrollment in the NEW CHOICE Study ahead of schedule. The rapid enrollment rate, 1500 women in eight weeks, reflects a broad interest amongst contraceptive users for the convenience of a once weekly contraceptive patch. We look forward to the continued progress of AG200-15 and anticipate the expedited timeline will enable us to file for FDA approval earlier than previously anticipated."

Dr. Marie Foegh, Chief Medical Officer and Vice President, Clinical Research and Development of Agile Therapeutics, stated, "Physicians perceive a large need among their patients for the comfort and convenience of Agile's low-dose, weekly contraceptive patch, and we are very pleased to potentially make our patch available earlier than anticipated. We extend a special thanks to the investigators of the study. Without their commitment to and support of the study, we would not have been able to complete enrollment in two months." Agile is working with DSP Clinical Research to manage the NEW CHOICE Study.

**About Kaiser Permanente Ventures:**

Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, makes investments in medical devices, healthcare services and information technology companies. Kaiser Permanente Ventures is dedicated to partnering with entrepreneurial companies to build innovative and enduring businesses that advance the quality and affordability of health care. Since its inception in 1997, Kaiser Permanente Ventures has invested in more than 25 venture-capital backed companies at all stages of development, and contributed organizational expertise, time and resources to the success of these companies. For additional information please visit [www.kpventures.com](http://www.kpventures.com).